A5081113647- Psychosomatic Disorders and Their Treatments
- Multiple Sclerosis Research Studies
- CNS Lymphoma Diagnosis and Treatment
- Bipolar Disorder and Treatment
- Mental Health and Psychiatry
- Peripheral Neuropathies and Disorders
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- S100 Proteins and Annexins
- Functional Brain Connectivity Studies
- Personality Disorders and Psychopathology
- Retinopathy of Prematurity Studies
- Children's Physical and Motor Development
- Diabetes and associated disorders
- Molecular Communication and Nanonetworks
- Suicide and Self-Harm Studies
- Neuroblastoma Research and Treatments
- Cancer Mechanisms and Therapy
- Intensive Care Unit Cognitive Disorders
- Neuroscience and Neuropharmacology Research
- Electroconvulsive Therapy Studies
- COVID-19 and Mental Health
- Protease and Inhibitor Mechanisms
- Neuroinflammation and Neurodegeneration Mechanisms
- Child Abuse and Trauma
- Calpain Protease Function and Regulation
Harvard University
2018-2024
Massachusetts General Hospital
2018-2024
Center for Neuro-Oncology
2024
Dana-Farber Cancer Institute
2024
University of Chicago
2022
Athinoula A. Martinos Center for Biomedical Imaging
2019
Benson-Henry Institute
2018
Johns Hopkins Medicine
2018
Johns Hopkins University
2018
Emory University
2017-2018
Objective Some individuals with functional neurological disorder (FND) exhibit motor and affective disturbances, along limbic hyper-reactivity enhanced motor-limbic connectivity. Given that the multimodal integration network (insula, dorsal cingulate, temporoparietal junction (TPJ)) is implicated in convergent sensorimotor, interoceptive processing, we hypothesised patients FND would altered amygdalar resting-state propagation to this network. Patient-reported symptom severity clinical...
Urokinase-type plasminogen activator (uPA) is a serine proteinase that, upon binding to its receptor (uPAR), catalyzes the conversion of into plasmin on cell surface. Our previous studies indicate that uPA and uPAR expression increase in ischemic brain during recovery phase from an acute injury promotes neurological after stroke. Here, we used male mice genetically deficient either (uPA-/-) or (uPAR-/-) with four-amino acid substitution growth factor domain abrogates (PlatGFDhu/GFDhu)...
Insecure attachment is a predisposing risk factor for the development of functional neurological disorder (FND). There limited research investigating connections between styles, other vulnerabilities, and symptom severity in patients with motor FND. By using within-group design prospective data collection, authors performed univariate tests followed by multivariate linear regressions to investigate neuropsychiatric factors associated four styles (secure, fearful, preoccupied, dismissing)...
Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of trials remains undefined. This study describes the real-world utilization mutant IDH1 inhibitor (IDHi), ivosidenib, patients with glioma. We retrospectively reviewed and radiographic data from treated ivosidenib monotherapy 2020 to 2024 at Dana-Farber Cancer Institute Massachusetts General Hospital. cohort included 74...
Cerebral ischemia causes the presynaptic release of tissue-type plasminogen activator (tPA). The postsynaptic density (PSD) is a structure that provides matrix where signaling transduction excitatory synapses takes place. protein-95 (PSD-95) most abundant scaffolding protein in (PSD), it modulates response to glutamate by regulating anchoring receptors PSD. We found tPA induces local translation PSD-95 mRNA and subsequent recruitment PSD, via plasminogen-independent activation TrkB...
Abstract INTRODUCTION Maximal safe resection standard of care treatment IDH-mutant gliomas and is associated with improved overall survival (OS). However, the impact extent (EOR) at first recurrence not well established there are no data on its prognosis. METHODS We retrospectively collected clinical patients WHO grade 2 astrocytoma oligodendroglioma treated our institution from 1997 to 2023. To assess EOR recurrence, we excluded who exclusively underwent diagnostic biopsy. Dates progression...
April 27, 2018April 10, 2018Free AccessContributors to Long-Term Disability in Patients with Neuromyelitis Optica Spectrum Disorder (P6.408)Michael Levy, Maureen Mealy, Sarah Mossburg, SU-Hyun Kim, Nadja Borisow, Reydmar Lopez, Juan Pablo Ospina, … Show All , Michael Scheel, Anusha Yeshokumar, Jacqueline Palace, Jorge Andres Jimenez-Arango, Friedemann Paul, and Ho Jin Kim FewerAuthors Info & AffiliationsApril 2018 issue90 (15_supplement)https://doi.org/10.1212/WNL.90.15_supplement.P6.408...
May 6, 2019April 9, 2019Free AccessIndividual Differences in Social Network Size Linked to Nucleus Accumbens and Hippocampal Volumes Motor Functional Neurological Disorders (P2.1-016)Juan Pablo Ospina, Rozita Jalilianhasanpour, Benjamin Williams, Ibai Diez Palacio, David L. PerezAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.P2.1-016 Letters the Editor
May 6, 2019April 9, 2019Free AccessCorticolimbic Fast-Tracking: Enhanced Multimodal Integration in Functional Neurological Disorder (P2.1-011)Ibai Palacio, Laura Ortiz-Teran, Benjamin Williams, Rozita Jalilianhasanpour, Juan Pablo Ospina, Bradford Dickerson, Matcheri Keshavan, W. Curt LaFrance, Jorge Sepulcre, and David PerezAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.P2.1-011 Letters to the Editor